MNPR vs. MBRX, EDSA, PTI, AADI, DRRX, HCWB, IMRX, ACXP, NRXP, and EYEN
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Moleculin Biotech (MBRX), Edesa Biotech (EDSA), Proteostasis Therapeutics (PTI), Aadi Bioscience (AADI), DURECT (DRRX), HCW Biologics (HCWB), Immuneering (IMRX), Acurx Pharmaceuticals (ACXP), NRx Pharmaceuticals (NRXP), and Eyenovia (EYEN). These companies are all part of the "medical" sector.
Moleculin Biotech (NASDAQ:MBRX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
Moleculin Biotech received 188 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 70.91% of users gave Monopar Therapeutics an outperform vote while only 53.16% of users gave Moleculin Biotech an outperform vote.
Moleculin Biotech currently has a consensus price target of $35.00, suggesting a potential upside of 633.75%. Monopar Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 227.28%. Given Monopar Therapeutics' higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Monopar Therapeutics.
In the previous week, Monopar Therapeutics had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 3 mentions for Monopar Therapeutics and 1 mentions for Moleculin Biotech. Monopar Therapeutics' average media sentiment score of 1.87 beat Moleculin Biotech's score of 1.21 indicating that Moleculin Biotech is being referred to more favorably in the media.
Monopar Therapeutics' return on equity of -87.19% beat Moleculin Biotech's return on equity.
Moleculin Biotech has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 6.7% of Moleculin Biotech shares are held by insiders. Comparatively, 41.6% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Moleculin Biotech beats Monopar Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
